An analysis of metastatic melanoma patients treated with anti-PD-1 agents (pembrolizumab and nivolumab) showed that a lack of PTEN in melanoma patients increased tumor growth as compared to the PTEN-expressing patients by decreasing T cell functions [27]. The gene discussed is PTEN; the disease is neoplasm.